Compare AbCellera Biologics Inc (ABCL) vs iShares MBS ETF (MBB) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

MBB (iShares MBS ETF) trades at $93.84, down 0.31% with a bearish technical outlook from moving averages. The ETF shows neutral oscillator signals with RSI at 46.40. Recent institutional activity includes mixed positioning changes, with Comerica Bank reducing its stake by 12.9% while Concurrent Investment Advisors increased its position by 75.4% in Q4 2026. The fund focuses on mortgage-backed securities and has maintained consistent dividend payments.

The outlook for MBB remains cautious due to bearish technical signals and mixed institutional sentiment. Investment opportunities include exposure to the real estate sector with a 4% monthly yield potential, though risks involve interest rate sensitivity and mortgage market volatility. The ETF's defensive characteristics may appeal to income-focused investors seeking diversification.